SUPN - Supernus Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
1.28B
Enterprise Value 3
1.37B
Trailing P/E
12.43
Forward P/E 1
16.81
PEG Ratio (5 yr expected) 1
0.32
Price/Sales (ttm)
3.13
Price/Book (mrq)
2.29
Enterprise Value/Revenue 3
3.36
Enterprise Value/EBITDA 6
8.88

Trading Information

Stock Price History

Beta (5Y Monthly) 1.51
52-Week Change 3-33.27%
S&P500 52-Week Change 325.85%
52 Week High 343.05
52 Week Low 319.35
50-Day Moving Average 323.40
200-Day Moving Average 326.50

Share Statistics

Avg Vol (3 month) 3706.12k
Avg Vol (10 day) 3531.22k
Shares Outstanding 552.46M
Float 50.71M
% Held by Insiders 13.38%
% Held by Institutions 199.02%
Shares Short (Dec 30, 2019) 46.39M
Short Ratio (Dec 30, 2019) 48.23
Short % of Float (Dec 30, 2019) 417.12%
Short % of Shares Outstanding (Dec 30, 2019) 412.19%
Shares Short (prior month Nov 28, 2019) 45.4M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2018
Most Recent Quarter (mrq)Sep 29, 2019

Profitability

Profit Margin 25.92%
Operating Margin (ttm)36.16%

Management Effectiveness

Return on Assets (ttm)9.09%
Return on Equity (ttm)21.61%

Income Statement

Revenue (ttm)408.24M
Revenue Per Share (ttm)7.80
Quarterly Revenue Growth (yoy)-0.80%
Gross Profit (ttm)393.54M
EBITDA 154.33M
Net Income Avi to Common (ttm)105.82M
Diluted EPS (ttm)1.96
Quarterly Earnings Growth (yoy)3.00%

Balance Sheet

Total Cash (mrq)296.7M
Total Cash Per Share (mrq)5.66
Total Debt (mrq)371.56M
Total Debt/Equity (mrq)66.68
Current Ratio (mrq)2.85
Book Value Per Share (mrq)10.62

Cash Flow Statement

Operating Cash Flow (ttm)132.19M
Levered Free Cash Flow (ttm)102.04M